[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiamen Ophthalmology Center Affiliated to Xiamen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":101},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100642544","artificial-intelligence-assisted-lesion-based-urgent-referral-triage-of-ultra-widefield-retinal-images-100642544",false,"NCT07643129","Artificial Intelligence-Assisted Lesion-Based Urgent Referral Triage of Ultra-Widefield Retinal Images","Clinical Utility of an Artificial Intelligence-Assisted Lesion-Based Urgent Referral Triage System for Ultra-Widefield Retinal Images: A Prospective Multi-Reader Multi-Case Randomized Reader Study","ALERT-UWF","Inclusion Criteria:\n\n* Licensed ophthalmologists\n* Willing to participate as readers\n* Completion of study training\n\nExclusion Criteria:\n\n* Retinal specialists involved in establishing gold-standard labels\n* Prior access to gold-standard labels\n* Incomplete study participation",true,"ALL","18 Years",{"count":21,"type":22},8,"ESTIMATED","INTERVENTIONAL",[25],"NA","his study evaluates the clinical utility of an artificial intelligence (AI)-assisted lesion-based urgent referral triage system for ultra-widefield (UWF) retinal images.\n\nUnlike disease-classification systems, the AI system identifies predefined vision-threatening retinal findings and generates lesion-level urgent referral recommendations. Participating ophthalmologists will evaluate UWF retinal images under randomized AI-assisted and unassisted conditions.\n\nThe primary objective is to determine whether lesion-based AI assistance improves urgent referral triage performance compared with unaided image interpretation.",[28,29,30,31,32,33],"Vision-Threatening Retinal Lesions","Urgent Referral Retinal Findings","Retinal Detachment","Pre-retinal Hemorrhage","Subretinal Hemorrhage","Retinal Neovascularization",[35,36,37,38,39,40],"Artificial Intelligence","Urgent Referral","Lesion-Based Triage","Ultra-Widefield Imaging","Clinical Decision Support","Multi-Reader Multi-Case Study","NOT_YET_RECRUITING","2026-06-10",{"date":44,"type":45},"2026-06-15","ACTUAL",{"date":44,"type":22},{"date":48,"type":22},"2026-06-30",{"name":50,"class":51},"Xiamen Ophthalmology Center Affiliated to Xiamen University","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":77,"locationsCount":78},"100640460","early-vitrectomy-vs-prp-in-early-proliferative-diabetic-retinopathy-100640460","NCT07586787","Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy","Comparison of Early Micro-invasive Vitrectomy Surgery Versus Panretinal Photocoagulation for the Treatment of Early Proliferative Diabetic Retinopathy: A Multi-center Randomized Trial","Inclusion Criteria:\n\n* Age 18 years or older.\n\nDiagnosis of type 2 diabetes mellitus.\n\nPresence of early proliferative diabetic retinopathy with active neovascularization, or mild vitreous hemorrhage or preretinal hemorrhage that does not interfere with evaluation of neovascularization.\n\nRelatively clear optical media, good pupillary dilation, and sufficient cooperation for panretinal photocoagulation and retinal imaging.\n\nAbility and willingness to provide written informed consent.\n\nIf both eyes are eligible, the eye with worse vision will be included.\n\nExclusion Criteria:\n\n* Prior panretinal photocoagulation, macular photocoagulation, or vitrectomy in the study eye.\n\nRetinal traction or retinal detachment.\n\nOptic neuropathy.\n\nMacular edema caused by reasons other than diabetes.\n\nCoexisting ocular disease that may decrease visual acuity during the study.\n\nSubstantial cataract likely to decrease visual acuity by more than three lines.\n\nMajor ocular surgery within the past 4 months or planned intraocular surgery within the next 6 months.\n\nYAG capsulotomy within the past 2 months.\n\nAny intravitreal injection within the past 3 months.\n\nAphakia.\n\nSevere external ocular infection.\n\nUncontrolled glaucoma.\n\nSignificant renal disease requiring dialysis or kidney transplantation.\n\nUnstable glycemic control.\n\nBlood pressure greater than 180\u002F110 mmHg.\n\nHistory of transient ischemic attack, stroke, myocardial infarction, acute congestive heart failure, or other acute cardiac event requiring hospitalization within the past 4 months.\n\nPregnant, lactating, or intending to become pregnant during the study period.\n\nParticipation in another clinical trial.\n\nUnwilling or unable to provide informed consent, undergo randomization, or return for scheduled visits.",{"count":60,"type":22},100,[25],"The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early proliferative diabetic retinopathy (PDR). It will also evaluate the safety and functional outcomes of early surgical intervention in this population.\n\nThe main questions it aims to answer are:\n\nDoes early MIVS increase the proportion of eyes achieving complete regression of retinal neovascularization at 12 months? Does early MIVS improve visual and functional outcomes, including visual acuity and visual field, compared to PRP? Researchers will compare early MIVS combined with peripheral scatter photocoagulation to standard PRP to determine whether early surgical intervention leads to better regression of neovascularization and improved clinical outcomes.\n\nParticipants will:\n\nReceive either MIVS with peripheral photocoagulation or standard PRP Undergo retinal imaging assessments including fundus fluorescein angiography (FFA) or optical coherence tomography angiography (OCTA) Complete follow-up visits over 12 months, including visual acuity testing, visual field testing, and optical coherence tomography (OCT) imaging Be monitored for the occurrence of vitreous hemorrhage and other clinical outcomes",[64],"Proliferative Diabetic Retinopathy (PDR)",[66,67,68,69],"Panretinal photocoagulation","Proliferative diabetic retinopathy","Retinal neovascularization","Vitrectomy","RECRUITING","2026-05-07",{"date":73,"type":45},"2026-05-14",{"date":75,"type":45},"2025-01-01",{"date":42,"type":22},{"name":50,"class":51},6,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100628083","a-study-to-evaluate-the-safety-and-effectiveness-of-perfluorohexyloctane-eye-drops-on-treatment-of-dry-eye-disease-ded-related-to-meibomian-gland-dysfunction-mgd-100628083","NCT07457021","A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD)","Treating Dry Eye Disease Related to Meibomian Gland Dysfunction With Perfluorohexyloctane Eye Drops : A Prospective, Multicenter, Real-world Study","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for meibomian gland dysfunction (MGD) as stipulated in the \"Expert Consensus on Diagnosis and Treatment of Meibomian Gland Dysfunction in China (2023)\"\n2. Patients who meet the diagnostic criteria for dry eye as stipulated in the \"Clinical Expert Consensus on Dry Eye in China (2020)\"\n3. Be at least 18 years old.\n4. Voluntarily participate in this study and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients who have a history of allergy to any component of the drugs or tests intended for use in the study (such as perfluorohexyloctane, fluorescein);\n2. Patients who used perfluorohexyloctane eye drops within 2 weeks before enrollment;\n3. Patients who have participated in or are currently participating in clinical trials of other drugs or devices within one month;\n4. Situations where researchers determine that may pose significant risks to patients, confuse the trial results, or seriously interfere with patients' participation in the trial (including language barriers).",{"count":87,"type":22},2000,"OBSERVATIONAL","Perfluorohexyloctane eye drops is the only drug in China approved for treating Dry Eye Disease (DED) related to Meibomian Gland Dysfunction (MGD), its efficacy and safety in the clinical practice of treating DED related to MGD in the real world, whether in combination with or without various other treatment methods (other drugs or physical therapy) , remain to be explored.\n\nThis study aims to collect data on the treatment of DED related to MGD with perfluorohexyloctane under real medical conditions. Through analysis, it seeks to obtain clinical evidence of the product's application value and potential benefits or risks, providing evidence for the treatment of DED elated to MGD with perfluorohexyloctane under real medical conditions.",[91],"Dry Eye Disease","2026-03-06",{"date":94,"type":45},"2026-03-09",{"date":96,"type":22},"2026-03-01",{"date":98,"type":22},"2029-09-30",{"name":50,"class":51},1,""]